Home / Market News / $ERNA

$ERNA news and market catalysts

The 5 most recent market catalysts affecting $ERNA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

5 catalysts 1 high impact 5 bullish 0 bearish Biotechnology
Sep 30, 2026 Corporate Catalyst Bullish Impact 75
Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine
Ernexa Therapeutics has released highly encouraging safety data for ERNA-101, its lead synthetic iMSC therapy. The successful completion of repeat-dose toxicology, tumorigenicity, …
Jul 15, 2026 Corporate Catalyst Bullish Impact 75
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
Ernexa Therapeutics (ERNA) reported that an independent preclinical study confirmed the efficacy of its ERNA-101 cell therapy in combination with PD-1 checkpoint inhibition, showin…
Jul 15, 2026 Corporate Catalyst Bullish Impact 85
Ernexa Therapeutics shares are trading higher after the company announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition.
The positive preclinical data for ERNA-101, especially in combination with PD-1 checkpoint inhibition, is a strong corporate catalyst for Ernexa Therapeutics. This validation signi…
Jul 15, 2026 Market Technicals Bullish Impact 55
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
This filing highlights pre-market trading activity for 12 health care stocks, showing considerable volatility with some experiencing gains of over 88% and others declines of over 3…
Jul 15, 2026 Corporate Catalyst Bullish Impact 75
Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3
Ernexa Therapeutics (ERNA) released positive preclinical data for its lead cell therapy candidate, ERNA-101, demonstrating complete tumor clearance and durable long-term survival i…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.